2007 Winning Paper
The 2007 RCGP Merck Sharp & Dohme Limited Research
paper of the year award was awarded to the
paper Early treatment with Prednisolone or
Acyclovir in Bell’s palsy.
The winners addressed the question of treatment for Bell’s
palsy, an alarming idiopathic weakness of the facial nerve from
which up to 30% of patients make an incomplete recovery. Treatment
to date has been with steroids or antiviral drugs, or both, but the
evidence base for their use is weak. This is an uncommon condition,
and the multidisciplinary research team developed a detailed
factorial study design randomising 551 patients within 3 days of
symptom onset to Prednisolone, Acyclovir, both drugs or
placebo. Their findings, published in the New England Journal
of Medicine, were that early treatment with Prednisolone
significantly improves the chances of complete recovery. There was
no evidence of benefit from Acyclovir, either alone or in addition
to Prednisolone. For those given steroids, 83% had recovered at 3
months, and 94% at 9 months.
Therapeutic studies of uncommon acute
conditions are particularly difficult to undertake, and the authors
succeeded with a very rigorous study, giving clinicians
reliable guidance for the first time on how Bell’s palsy should be
managed. This is particularly important for a condition that
usually is presented first to the GP, who has to make an immediate
decision on management. The paper is a shining example
of the level of scientific excellence that can be achieved by
general practice research in the UK.
Read
the winning paper
here

The 2007 Research Paper of the
Year winning authors with RCGP and MSD representatives
2007 Highly Commended Paper
The rules of the award mean that the panel
may, in exceptional circumstances, highly commend a paper. In
recognition of the scientific quality and the complexity of
execution, this year’s panel chose to commend the paper
Warfarin versus aspirin for stroke prevention in an elderly
community population with atrial fibrillation (the Birmingham
Atrial Fibrillation Treatment of the Aged Study, BAFTA): a
randomised controlled trial. This paper, published in
the Lancet, demonstrated the value of anticoagulation therapy for
people over the age of 75 who have atrial fibrillation; a condition
often identified for the first time in primary care. In
managing the care of an increasingly aged population, this is a key
message for practising clinicians.
circ@rcgp.org.uk
0203 170 8231